Tierney A, Cuff P, Kotler DP; International Conference on AIDS.
Int Conf AIDS. 1991 Jun 16-21; 7: 247 (abstract no. M.B.2263).
St. Luke's-Roosevelt, Columbia P&S, NY, NY, USA
OBJECTIVE: To determine the effect of Megace on weight, lean body mass, body fat, appetite, immunologic function and quality of life. METHODS: AIDS subjects with a greater than or equal to 10% weight loss were randomized to receive a daily dose of 100, 400 or 800 mg of Megace (Bristol-Myers USP) or placebo during a three month double-blind trial. RESULTS: Nineteen of 21 evaluable treated subjects gained weight (1.5 - 29 lbs), while those randomized to receive placebo continued to lose weight. The 2 treated subjects who lost weight had developed an esophageal ulcer and histoplasmosis, respectively. Megace was associated with weight gain with a linear dose response relationship (p = 0.0094). An increase in both lean body mass and body fat was detected using bioelectrical impedance analysis. Weight gain was associated with an increase in appetite and food intake. No improvements in CD3+, CD4+, CD8+ counts or skin reactivity was seen. While Karnofsky scores did not change, improvement in perceived quality of life was associated with weight gain. CONCLUSIONS: Megace is associated with dose-related weight gain in people with AIDS with no other active infections or complications. Nutritional repletion included lean body mass as well as fat. No improvement in immunologic function was associated with weight gain although quality of life was enhanced.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Appetite
- Appetite Stimulants
- Body Composition
- Body Weight
- Cachexia
- Double-Blind Method
- Electric Impedance
- Karnofsky Performance Status
- Life
- Megestrol Acetate
- Nutritional Status
- Quality of Life
- Weight Gain
- Weight Loss
Other ID:
UI: 102183184
From Meeting Abstracts